Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $67.78

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $67.7778.

CRSP has been the subject of several research analyst reports. Citizens Jmp reaffirmed a “market outperform” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. Sanford C. Bernstein lifted their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Evercore restated an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a research note on Monday, May 11th. Finally, Truist Financial raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in CRSP. Versant Capital Management Inc grew its stake in CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after buying an additional 296 shares in the last quarter. Mcguire Capital Advisors Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $26,000. Rothschild Investment LLC lifted its holdings in CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. boosted its stake in CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after purchasing an additional 382 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $60.77 on Wednesday. The business’s 50 day simple moving average is $53.16 and its 200 day simple moving average is $53.13. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. CRISPR Therapeutics has a one year low of $44.12 and a one year high of $78.48. The stock has a market capitalization of $5.86 billion, a PE ratio of -9.77 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million for the quarter. As a group, research analysts forecast that CRISPR Therapeutics will post -4.89 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.